Mouth/throat symptoms: Oral topical: Lozenge: Slowly dissolve 1 lozenge in mouth every 2 hours as needed (maximum: 10 lozenges/day)
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Dyclonine: Pediatric drug information")
Mouth/throat symptoms: Approved ages varies by product; product-specific dosing:
Lozenge 2 mg: Children ≥6 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day
Lozenge 2 mg (with menthol 5 mg and pectin 6 mg): Children ≥4 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day
Lozenge 3 mg (with menthol 6 mg): Children ≥4 years and Adolescents: Oral topical: Slowly dissolve one lozenge in mouth every 2 hours as needed; maximum daily dose: 10 lozenges/day
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
Yes
Allow lozenge to slowly dissolve in mouth.
Topical: Allow lozenges to slowly dissolve in mouth.
Cough: Temporary relief of cough associated with a cold or inhaled irritants.
Mouth/throat symptoms: Temporary relief of occasional mouth and throat symptoms (eg, minor irritation, pain, sore throat and sore mouth); protection of irritated areas in sore mouth and throat.
Dyclonine may be confused with dicyclomine
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Central nervous system: Feeling hot, localized numbness, localized warm feeling, sensation of cold
Gastrointestinal: Burning sensation of mouth
Hypersensitivity: Hypersensitivity reaction
Local: Local irritation, local pain
Other warnings/precautions:
• Self-medication (OTC use): When used for self-medication (OTC), discontinue use and contact health care provider if sore throat is severe, sore mouth symptoms last >2 days, or occurs with or following fever, headache, rash, nausea, or vomiting; sore mouth symptoms lasting for >7 days; irritation, pain, or redness persists or worsens; or swelling, rash or fever develops; cough lasts >7 days, comes back, or occurs with fever or persistent headache. Consult a health care provider before use for cough that lasts or is chronic (eg, cough that occurs with smoking, asthma, emphysema) or cough that occurs with too much mucous.
Dosage forms specific issues:
• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.
• Tartrazine: Some formulations may contain FD&C yellow #5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those with aspirin sensitivity.
Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).
None known.
Bupivacaine: Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine. Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand). Risk C: Monitor therapy
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Local anesthetic that produces reversible loss of sensation by preventing or diminishing the conduction of nerve impulses near application site.
